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S U M M A R Y
Objectives: Recommended doses of liposomal amphotericin B (L-AMB) range from 3 to 6 mg/kg/day, but
1 mg/kg/day may be equally effective and a lower cost alternative for many indications. The objective
of this analysis was to assess indications and clinical outcomes of patients who received low-dose
(1 mg/kg/day rounded up in 50-mg increments) and standard-dose (2 mg/kg/day) L-AMB.
Methods: This was a retrospective analysis of adult L-AMB recipients with suspected invasive fungal
infections (IFI) at a single center from 2006 to 2011. The primary outcome was clinical response at the
end of treatment. Secondary outcomes included survival and toxicity. Results were analyzed using
Chi-square and descriptive statistics.
Results: Of 89 adult L-AMB recipients included, 36 had proven or probable IFIs. Nineteen (53%) received
low doses and 17 (47%) received standard doses. Median doses were 1.5 and 3.0 mg/kg/day.
Cryptococcus was the most common fungal pathogen in the low-dose group (37%), and Candida spp. in
the standard-dose group (47%). Forty-seven percent of subjects in both groups improved clinically. Sixty-
eight percent of low-dose recipients and 76% of standard-dose recipients survived to discharge. Rates of
nephrotoxicity and hypokalemia were comparable.
Conclusions: Comparable rates of clinical improvement, survival to discharge, and toxicity were
identiﬁed among low- and standard-dose L-AMB recipients.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Although lipid-based amphotericin B formulations are routine-
ly used in the treatment of invasive fungal infections (IFI), the
optimal dose for these indications has not yet been established.
The manufacturer of liposomal amphotericin B (L-AMB) recom-
mends doses ranging between 3 and 6 mg/kg daily, with lower
doses, 3 mg/kg daily, recommended for empiric treatment, and the
highest dose, 6 mg/kg daily, recommended for the treatment of
cryptococcal meningitis.1 However, recent clinical trials have
suggested that L-AMB doses as low as 1 mg/kg daily are effective
both empirically and for the treatment of various invasive
infections.2–4 Because drug acquisition costs and potentially the
risk of toxicity of L-AMB are increased at higher doses, using doses
in the lower range of those shown to be effective is a rational
antimicrobial stewardship strategy.§ Presented as an abstract at the 22nd Annual European Congress for Clinical
Microbiology and Infectious Diseases, London, UK, March 31, 2012.
* Corresponding author. Tel.: +1 312 996 0892; fax: +1 312 413 1797.
E-mail address: danziger@uic.edu (L.H. Danziger).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.01.015In 2002, L-AMB was added to the formulary of John H. Stroger Jr.
Hospital of Cook County (JSH), a 465-bed, level I trauma center,
with eight intensive care units (ICUs), including a burn ICU, which
primarily serves indigent patients in Chicago, Illinois. At that time
L-AMB (AmBisome, Gilead Sciences Inc., San Dimas, CA, USA) was
available only in 50-mg vials that cost US$ 152. Thus, for a 70 kg
patient, a 7-day course of 100 mg (1.4 mg/kg) daily cost US$ 2128,
whereas a 7-day course of 200 mg (2.9 mg/kg) daily cost US$ 4256
and a 7-day course of 350 mg (5 mg/kg) daily cost US$ 7448. To
mitigate these costs, L-AMB was restricted at JSH to patients seen
by the infectious diseases service, which followed a policy
promoting the use of 1 mg/kg/day, rounded upward in 50 mg
increments, for indications for which higher doses had not been
demonstrated to be more effective, including cryptococcosis,
aspergillosis, and empiric therapy for neutropenic fever refractory
to broad-spectrum antibiotics. Doses greater than 100 mg daily
required approval from the chief of infectious diseases. This policy
was recommended by the Anti-Infective Committee (of which the
senior author was the chair) and was approved by its Drug and
Formulary and Executive Medical Staff committees at JSH.
The objective of this analysis was to assess the indications and
clinical outcomes of patients who received low- and standard-doseses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Subjects included.
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noteworthy differences in apparent L-AMB efﬁcacy or toxicity in
the two patient groups.
2. Methods
This retrospective analysis included all adult patients who
received L-AMB between January 2006 and April 2011 when fully
electronic medical records were available at JSH; L-AMB recipients
before 2006 were excluded because of limited access to their paper
medical records. Study data were collected and managed using
REDCap electronic data capture tools hosted at the University of
Illinois at Chicago.5 Subjects at least 18 years old and who received
at least one day of L-AMB therapy were identiﬁed by pharmacy
records. Those who received amphotericin B deoxycholate (AMBd)
during the same admission were excluded. Each subject was
included in the analysis only one time; admissions for additional
courses of L-AMB were excluded from analysis. Patients were
analyzed in two groups according to the initial dose of L-AMB
received. Following the low-dose policy, most patients received
between 1.0 and 2 mg/kg/day, therefore we deﬁned low-dose as
<2 mg/kg/day and standard-dose as 2 mg/kg/day. Patients were
categorized as having possible, probable, or proven fungal
infections by 2009 European Organization for Research and
Treatment of Cancer (EORTC) and Mycology Study Group (MSG)
diagnostic criteria for IFIs.6 For cryptococcal meningitis, the
EORTC/MSG guidelines provide speciﬁc criteria only for proven
infections. Therefore we speciﬁed criteria for probable cryptococ-
cal meningitis as a serum cryptococcal antigen (sCRAG) >1:8,
symptomatic presentation, and an opening pressure >200
mmH2O. Criteria for possible cryptococcal meningitis included a
sCRAG >1:8 and clinical suspicion of infection. The study protocol
was approved by the institutional review boards of JSH and the
University of Illinois at Chicago Medical Center.
Background characteristics, including relevant medical history
as documented in the medical chart were also collected. To assess
the subject’s severity of illness, four criteria were assessed within
24 h of initiating treatment with L-AMB: admission to an ICU,
mechanical ventilation, vasopressors or inotropes prescribed, and
renal replacement therapy (including intermittent or continuous
hemodialysis).
2.1. Efﬁcacy analysis
Efﬁcacy, including clinical response and survival, was limited to
subjects with probable or proven fungal infections. The primary
outcome was clinical response, including both cure and improve-
ment, at the end of treatment. Clinical cure was deﬁned as the
resolution of signs and symptoms, including fever, and microbio-
logic eradication. Subjects categorized as clinically improved had a
reduction of their fever, stabilization of signs and symptoms, and
microbiologic eradication. Finally, subjects who met one of any of
the following criteria were classiﬁed as clinical failures: persis-
tently positive cultures, worsening or no change in their
symptoms, a breakthrough fungal infection, or a dose escalation
of L-AMB. Survival was evaluated at hospital discharge.
2.2. Toxicity analysis
Rates of nephrotoxicity and hypokalemia were evaluated
among all subjects included in the study. Nephrotoxicity was
deﬁned as a doubling of serum creatinine to a value of at least
1.2 mg/dL amongst subjects who were not already on renal
replacement therapy. Hypokalemia was deﬁned as a serum
potassium level of <3.0 mEq/L. Exposure to concomitant nephro-
toxins and potassium-wasting medications was documented.We could not record rates of infusion-related reactions because
they were documented inconsistently in patient records.
2.3. Statistics
Outcomes were evaluated with Chi-square and descriptive
statistics. For low frequency outcomes, a two-tailed Fisher’s exact
test was utilized. A p-value of <0.05 was considered statistically
signiﬁcant.
3. Results
One hundred and twenty-eight L-AMB recipients were identi-
ﬁed from pharmacy records; of these, 39 were excluded (Figure 1).
Of the 89 remaining subjects, 58 received low-dose L-AMB and 31
received standard-dose L-AMB. Of these, 19 and 17 subjects in the
low- and standard-dose groups, respectively, met criteria for
proven or probable infection and were included in the efﬁcacy
analysis. Baseline characteristics of the overall study population
are presented in Table 1. The majority of subjects in both groups
were males, with a median age in the mid-forties. The most
common underlying conditions were HIV/AIDS and hematologic
malignancies. Over half of all subjects in both groups were
admitted to the ICU at the time L-AMB therapy was initiated, with
many requiring mechanical ventilation and vasopressor and/or
inotrope support (Table 1). The median L-AMB dose in the low-
dose group was 1.5 mg/kg/day and in the standard-dose group was
3.0 mg/kg/day. The median duration of therapy was 6 days in the
low-dose group and 7 days in the standard-dose group. Of the 39
and 14 subjects with suspected but unconﬁrmed fungal infections
in the low- and standard-dose groups, 67% and 79%, respectively,
had non-fungal etiologies conﬁrmed for their illnesses.
3.1. Efﬁcacy analysis
Forty-seven percent of subjects with proven or probable fungal
infections in both low-dose and standard-dose L-AMB groups met
criteria for clinical cure or improvement (Figure 2). Background
characteristics were similar to those of the overall population,
although more subjects treated for probable or proven fungal
infections had a history of invasive fungal disease prior to
hospitalization than did patients treated for possible fungal
infection (12/36 (33%) vs. 3/53 (6%), p = 0.001). Notably, there
were more subjects with AIDS in the low-dose compared to the
standard-dose group, p = 0.01. Utilization of intensive care services
was more frequent among subjects with possible fungal infections
Table 1
Baseline characteristicsa
Characteristic Overall study population Subjects with proven or probable infections
<2 mg/kg/day
(n = 58)
2 mg/kg/day
(n = 31)
<2 mg/kg/day
(n = 19)
2 mg/kg/day
(n = 17)
Age, years, median (range) 45.5 (19–83) 42.5 (23–69) 42 (26–64) 43 (23–64)
Male 45 (78) 18 (58) 14 (74) 10 (59)
Black 31 (53) 15 (48) 9 (47) 7 (41)
Caucasian 7 (12) 3 (10) 3 (16) 6 (35)
Hispanic 18 (31) 11 (35) 5 (26) 18 (31)
Other 2 (4) 2 (6) 2 (10) 2 (12)
HIV/AIDS 25 (43) 7 (23) 10 (53)b 2 (12)
CD4 count, cells/mm3, median (range) 35 (6–495) 71 (5–403) 25.5 (6–214) 38 (5–71)
Hematologic malignancy 17 (29) 9 (29) 4 (21) 6 (35)
History of invasive fungal disease 9 (16) 6 (19) 8 (42) 4 (24)
Diabetes mellitus 8 (14) 4 (13) 1 (5) 3 (18)
Chronic corticosteroids 8 (14) 2 (12) 2 (11) 2 (12)
Neutropenia (ANC <0.5  109/L) 11 (19) 6 (19) 3 (16) 3 (18)
Admitted to the ICU 39 (67) 18 (58) 7 (37) 8 (47)
Mechanically ventilated 37 (64) 15 (48) 5 (26) 5 (29)
Received vasopressors and/or inotropes 29 (50) 8 (26)b 3 (16) 3 (18)
On renal replacement therapy prior to initiating L-AMB 9 (16) 1 (3) 2 (11) 0 (0)
Dose, mg/kg/day, median (range) 1.46 (0.57–1.96) 3.04 (2.04–5.38) 1.46 (0.97–1.85) 3.03 (2.09–5.14)
Duration of therapy, days, median (range) 6 (1–39) 7 (1–30) 9 (1–39) 9 (1–30)
ANC, absolute neutrophil count; ICU, intensive care unit.
a Results are n (%) unless otherwise speciﬁed.
b p < 0.05, comparing low-dose versus standard-dose recipients.
Table 2
Infections and pathogens among patients with proven or probable fungal infections
<2 mg/kg/day
(n = 19)
2 mg/kg/day
(n = 17)
Pathogens, n (%)
Aspergillus 3 (16) 3 (18)
Candida 5 (26) 8 (47)
Cryptococcus 7 (37) 3 (18)
Histoplasma/Blastomyces 3 (16) 2 (12)
Coccidioides 1 (5) 1 (6)
Mucormycosis 1 (5) 1 (6)
Infection syndromes, n (%)
Disseminated 3 (16) 4 (24)
Endocarditis 1 (5) 1 (6)
Fungemia/candidemia 2 (11) 4 (24)
Meningitis 6 (32) 4 (24)
Osteomyelitis 1 (5) 2 (12)
Pneumonia 7 (37) 5 (29)
Other 3 (16) 3 (18)
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15/36 (42%), p = 0.0007); however, rates of ICU admission and
intensive care support were similar between subjects who
received either low- or standard-dose L-AMB, p = 0.5 (Table 1).
Median L-AMB doses were comparable to the overall group;
however the median duration of therapy was longer in patients
with probable or proven infections, 9 days, compared to patients
with possible infections, 6 days.
The two most common sites of infection were pneumonia and
meningitis; Candida and Cryptococcus accounted for 36% and 28%
of the proven or probable infections, respectively (Table 2). Eight of
10 cryptococcal infections were meningitis, of which ﬁve were
treated with low-dose L-AMB, (median 1.46 mg/kg/day, range
1.16–1.69 mg/kg/day) for a median of 5.5 days, and three received
standard-dose L-AMB (median 2.94 mg/kg/day, range 2.75–
5.38 mg/kg/day) for a median of 5 days. All patients with
cryptococcal meningitis received concomitant ﬂucytosine.
The distribution of causes for treatment failure among patients
with proven or probable fungal infection was similar between low-
and standard-dose L-AMB groups (p > 0.2), with the exception of
persistently positive cultures, which occurred more frequently in
standard-dose recipients compared to low-dose recipients (5/17
(29%) vs. 0/19 (0%), p = 0.02) (Figure 3).
Of patients with proven or probable fungal infections, 13/19
(68%) subjects in the low-dose group and 13/17 (76%) subjects in
the standard-dose group survived to hospital discharge (p > 0.2,
Figure 2). All non-survivors were either critically ill when L-AMB
was initiated and/or had severe, immunocompromising co-
morbidities (Table 3).Figure 2. Clinical outcome and survival in patients with proven or probable
infections.Among patients with proven or probable fungal infection who
survived to hospital discharge, 18 (67%) were consolidated from
L-AMB to azole therapy to continue their course of antifungal
treatment. One patient completed therapy with L-AMB during
hospitalization and seven continued L-AMB therapy after hospital
discharge, either at home or in a long-term care facility.Figure 3. Reasons for treatment failure in patients with proven or probable
infections.
Table 3
Characteristics of patients who did not survive hospitalization
Age
(years)
Sex Major
comorbidities
Clinical status at L-AMB
initiation
Infection site, cause L-AMB dose
(mg/kg/day)
L-AMB
duration
(days)
Cause
of death
Comment
Low-dose recipients
49 F Relapsed ALL,
neutropenia
Mechanically ventilated, on
pressors, for progressive
pneumonia refractory to broad-
spectrum antibiotics
Pneumonia,
Aspergillus ﬂavus
1.0 1 Progressive
pneumonia,
multi-organ
failure
L-AMB changed to
voriconazole 1 day
before death
32 M AIDS Lucid, treated on ﬂoor for
relapsed cryptococcal
meningitis with intracranial
hypertension
Meningitis,
Cryptococcus
neoformans
1.7 10 Multiple seizures,
intracranial
hypertension
Flucytosine
co-administered;
daily lumbar
punctures
performed
63 F Glomerulonephritis
requiring
corticosteroids,
diabetes
Mechanically ventilated for
witnessed aspiration, ARDS,
receiving hemodialysis
Candida glabrata
bloodstream infection,
disseminated and
cutaneous
mucormycosis
1.8 16 Multiple organ
failure
Caspofungin given
for 36 days for
recurrent
multispecies
candidemia before
change to L-AMB
50 F AIDS, Hodgkin’s
lymphoma
Mechanically ventilated for
bilateral pneumonia despite
ﬂuconazole therapy
Pneumonia,
Cryptococcus
neoformans
1.4 1 Respiratory
failure
Received
ﬂuconazole for 7
days before L-AMB
was started
Standard-dose recipients
55 F Hodgkin’s lymphoma,
stage IV
Mechanically ventilated for
progressive bilateral
pneumonia refractory to broad-
spectrum antibiotics
Pneumonia, Aspergillus
species
5.1 3 Respiratory
failure
Voriconazole
substituted for
L-AMB 5 days
before death
51 M Sarcoidosis,
pulmonary
aspergillomas
Mechanically ventilated for
massive hemoptysis
Bilateral upper lobe
aspergillomas
3.0 7 Bacterial VAP,
multi-organ
failure
Voriconazole given
concurrently with
L-AMB
51 M Relapsed AML,
neutropenia
Stable on ﬂoor Sinusitis, Aspergillus
species
5.1 3 Multiple organ
failure
L-AMB changed to
voriconazole 3 days
before death
43 M Stem-cell transplant
for CML, GVHD,
toxic epidermal
necrolysis
Mechanically ventilated on
burn intensive care unit
Pneumonia, presumed
aspergillosis (positive
galactomannan assay)
3.0 7 Multiple organ
failure
L-AMB changed to
voriconazole 9 days
before death
24 F Injection drug use,
recent mitral,
tricuspid valve
surgery for
endocarditis
Mechanical ventilation with
acute renal failure,
disseminated intravascular
coagulation
Endocarditis, Candida
albicans
2.0 7 Multiple organ
failure
L-AMB 100 mg
daily given to 50 kg
patient;
reoperation
deemed infeasible
24 F Untreated Crohn’s
disease
Mechanical ventilation,
pressor-dependent
Intra-abdominal sepsis,
Candida albicans
3.6 2 Multiple organ
failure
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ARDS, acute respiratory distress syndrome; CML, chronic myeloid leukemia; F, female; GVHD, graft versus
host disease; L-AMB, liposomal amphotericin B; M, male; VAP, ventilator-associated pneumonia.
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Among all subjects, 11 (19%) and 8 (26%) subjects in the low-
and standard-dose groups, respectively, met the deﬁnition for
nephrotoxicity (p > 0.2); two patients in both groups required
renal replacement therapy. Hypokalemia was marginally less
frequent in the low-dose group than in the standard-dose group
(3/58 (5%) vs. 6/31 (19%), p = 0.06). Receipt of concomitant
nephrotoxins or potassium-wasting medications did not vary
signiﬁcantly between low- and standard-dose recipients (p > 0.2).
Overall, L-AMB was discontinued in six patients in the low-dose
group and one patient in the standard-dose group due to toxicity.
4. Discussion
Although liposomal amphotericin B is associated with substan-
tially lower rates of toxicity – principally nephrotoxicity,
hypokalemia, and infusion reactions – than amphotericin B
deoxycholate, few data demonstrate that the 3–6 mg/kg/day of
amphotericin B recommended by the L-AMB manufacturer are
associated with greater antifungal efﬁcacy than 1 mg/kg/day
of AMBd.2,7–9 This fact, coupled with the very high anddose-dependent cost of L-AMB prompted us to limit L-AMB dosing
to 1–2 mg/kg/day for many indications, intending to reserve the
higher manufacturer-recommended doses for fungal infections
with a theoretical beneﬁt from higher doses (e.g., non-cryptococcal
central nervous system infections).
In this clinically heterogeneous cohort of patients, low-dose
L-AMB therapy was given to the majority (58/89; 65%) of eligible
adult L-AMB recipients and, among the 36 patients with probable
or proven fungal infection, was associated with identical rates of
clinical cure or improvement and similar rates of survival to
hospital discharge as those seen among standard-dose L-AMB
recipients (Figure 2). Nephrotoxicity was observed in 19 (21%) of
89 L-AMB recipients, with similar rates among low- and standard-
dose L-AMB recipients. Although the standard-dose recipients
were diagnosed with probable or conﬁrmed IFIs more often than
the low-dose group, immunocompromising comorbidities and the
need for intensive care occurred with similar frequencies in the
two groups (Table 1). Thus, there is little to suggest that low-dose
L-AMB was associated with poorer outcomes.
Experience with low-dose liposomal amphotericin B has been
described previously.2,4,7,8 In two prospective, multicenter, ran-
domized trials including 338 adult and pediatric subjects with
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Prentice et al. found no statistically signiﬁcant differences in
clinical response between patients treated with 1 mg/kg/day and
3 mg/kg/day of L-AMB.2 Both Ellis et al. and Ringden et al.
evaluated low-dose L-AMB for the treatment of patients with
IFIs.4,10 Ellis et al. found no statistically signiﬁcant differences in
survival or clinical outcome in 87 neutropenic patients with
invasive aspergillosis randomized to either 1 mg/kg or 4 mg/kg of
L-AMB.4 Forty-nine percent and 46% of patients in the 1 mg/kg/day
and 4 mg/kg/day groups, respectively, had a complete clinical
response.4 However, the criteria used to deﬁne a probable
Aspergillus infection included only clinical, radiographic, and host
criteria (e.g. neutropenic patients and those with solid or non-solid
tumors) but did not include mycological criteria recommended by
the 2008 EORTC guidelines, which we followed.6 Using these
criteria, only 20 of the 87 subjects described by Ellis et al.4 had
proven or probable invasive Aspergillus, whereas all 36 patients
with proven or probable IFIs described in this report, of whom six
had aspergillosis, met EORTC mycological criteria. In an observa-
tional study, Ringden et al. reported a 58% rate of cure among 37
patients with proven and 14 patients with presumed IFIs who
received a median daily dose of 2.2 mg/kg.10.
Although previously published low-dose L-AMB data show
rates of favorable clinical outcomes that are comparable to
outcomes with higher doses, the majority of patients included
in the trials had either invasive aspergillosis or candidiasis.4,7,10,11
Thus, based on these data, it is difﬁcult to extrapolate the use of
low-dose L-AMB for use in other IFIs. Additionally, the availability
of voriconazole and ﬂuconazole/echinocandin antifungal agents
and their respective roles as the treatment standard for invasive
aspergillosis and candidiasis, renders low-dose amphotericin for
treatment of these infections less relevant.12,13 In the current
study, infections with either Cryptococcus or Candida comprised
greater than 50% of the proven or probable infections, and
differences in clinical outcomes were not found between low
and standard doses of L-AMB.
The use of low-dose L-AMB for cryptococcal meningitis is
particularly interesting, as this is the indication for which the
highest doses of the drug have been recommended.1 A recent
multicenter, double-blind, randomized controlled trial evaluated
267 patients with cryptococcal meningitis.3 The authors demon-
strated non-inferiority in both clinical and microbiological out-
comes with 3 mg/kg/day of L-AMB monotherapy compared to
6 mg/kg/day of L-AMB and amphotericin B deoxycholate (AMB-d)
0.7 mg/kg/day for induction therapy.3 The 2010 Infectious Diseases
Society of America (IDSA) treatment guidelines for cryptococcal
meningitis recommend 0.7–1.0 mg/kg/day of AMBd or L-AMB
dosed between 3 and 4 mg/kg/day for induction therapy.14
In 2010, a small randomized trial evaluating 17 patients with
HIV and cryptococcal meningitis in India compared doses of 1 and
3 mg/kg/day of Fungisome, an Indian formulation of liposomal
amphotericin B, and found no statistically signiﬁcant differences in
clinical response at 8 weeks.15 The time to clinical response was
longer amongst patients receiving 1 mg/kg/day (13 days) com-
pared to those who received 3 mg/kg/day (9 days).15 While these
data support lower dosing of liposomal amphotericin B, it is
important to note that this formulation may have different
pharmacologic properties, and therefore dosing ranges, compared
to the clinically available formulation of liposomal amphotericin B
(AmBisome) in the USA.16
Lipid formulations of amphotericin B vary.17,18 Amphotericin B
has been described as a concentration-dependent antifungal
agent.19 Thus, although higher concentrations achieved in the
serum result in greater fungal killing, as demonstrated in a
neutropenic mouse thigh model, this has not been corroborated for
clinical outcomes. In two 2002 publications, Bekersky andcolleagues compared the pharmacokinetics of 2 mg/kg of L-AMB
and 0.6 mg/kg of AMBd given as a single dose in healthy
volunteers.20,21 The highest total concentration (Cmax) of ampho-
tericin B achieved in subjects who received L-AMB was 22.9 mg/ml
compared to 1.43 mg/ml in subjects who received AMBd.20 In an
analysis of the pharmacologically active, freely available ampho-
tericin B (non-protein or liposome bound), the Cmax was
statistically higher in the AMBd group (0.06 mg/ml) compared to
the L-AMB group (0.016 mg/ml).21 However, the authors also noted
that duration of exposure to amphotericin B in a liposomal
formulation was longer than that in the amphotericin B
deoxycholate formulation.21 Thus the liposome serves as a slow-
release depot formulation of amphotericin B with lower concen-
tration peaks compared with AMBd.18 Given that statistically
signiﬁcant improvements in clinical outcomes have not been
demonstrated with AMBd compared to a range of doses of L-AMB,
it is possible that high peak serum concentrations of amphotericin
B may not be a requirement for clinical success.3,7–10,22,23
There are important limitations associated with this retrospec-
tive analysis of a relatively small cohort of adult L-AMB recipients
in a single center. Among patients with probable or conﬁrmed
infections, pathogens and sites of infections varied considerably.
Also, because L-AMB doses were selected by treating physicians
rather than being allocated randomly as in a controlled trial,
patients treated with higher doses may have had more severe
infections or comorbid diseases, though the rates of immunocom-
promise and comorbid diseases and the need for intensive care
were similar in the two groups (Table 1). Finally, treatment of IFIs
often requires long courses of maintenance therapy, but we were
not able to analyze patient outcomes after they were discharged
from the hospital.
In conclusion, our data corroborate the ﬁndings of controlled
clinical trials suggesting that low-dose L-AMB is a viable and cost-
effective treatment strategy for the management of IFIs.1,2,4
Although there has been an overall decrease in the use of
amphotericin B across US institutions due to the availability of
expanded-spectrum azoles and echinocandins, certain indications,
notably cryptococcal meningitis and neutropenic fever of un-
known cause refractory to empiric antibacterial therapy, continue
to warrant treatment with amphotericin B. However, prospective
randomized studies are needed to conﬁrm the effectiveness of this
dosing strategy.
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